Ascletis Pharma Inc.
Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potentially best-in-class and first-in-class therapeutics to treat metabolic diseases.
Last updated October 12, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potentially best-in-class and first-in-class therapeutics to treat metabolic diseases. It uses proprietary technologies including Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT), and has developed multiple drug candidates in-house, including small molecules and peptides. Its stated vision is to become the most innovative world-class biomedical company addressing global unmet medical needs in the area of metabolic diseases.
History
Ascletis Pharma Inc. is a fully integrated biotechnology company based in Hangzhou, China, focused on the development and commercialization of potentially best-in-class and first-in-class therapeutics to treat metabolic diseases. The company has built its drug discovery and development capabilities around three proprietary technology platforms: Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), the Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Using these platforms, Ascletis has developed multiple drug candidates in-house, spanning both small molecules and peptides. Ascletis' lead program is ASC30, a once-daily oral small molecule GLP-1R agonist for chronic weight management and diabetes. The company has also advanced a family of fixed-dose combinations built on ASC30, including ASC30_48FDC, a once-daily oral small molecule dual agonist combining ASC30 (GLP-1R agonist) and ASC48 (GIPR agonist); ASC30_48_39FDC, a once-daily oral small molecule triple agonist combining ASC30, ASC48, and ASC39 (an amylin receptor agonist, or SARA); and ASC30_39FDC, a once-daily oral small molecule dual agonist combining ASC30 and ASC39. In addition, the pipeline includes ASC39, an eloralintide-like potent selective amylin receptor agonist (SARA) designed as a once-daily oral small molecule; ASC36, an amylin peptide designed for once-monthly to once-quarterly subcutaneous administration and once-daily oral administration; and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual agonist. Beyond metabolic diseases, Ascletis has historically pursued immune diseases and exploratory indications, and it has maintained a commitment to viral hepatitis elimination, aligning with the World Health Organization's goal to eliminate viral hepatitis as a major public health threat by 2030. The company describes its vision as becoming the most innovative world-class biomedical company addressing global unmet medical needs in the area of metabolic diseases, and it states that its values are integrity, courage, excellence, and collaboration. Ascletis operates as a fully integrated organization, covering drug discovery, development, and commercialization, and it engages with domestic and global partners. Its investor relations activities include financial reporting, filings, upcoming events, corporate presentations, and scientific presentations. The company is headquartered in Hangzhou, China.
Ascletis Pharma Inc. is headquartered in Hangzhou, China, and operates as a fully integrated biotechnology company.
Ascletis develops its proprietary AISBDD, ULAP, and POTENT technology platforms for drug discovery and development.
Ascletis advances ASC30, a once-daily oral small molecule GLP-1R agonist, as its lead program for chronic weight management and diabetes.
Ascletis develops fixed-dose combinations including ASC30_48FDC, ASC30_48_39FDC, and ASC30_39FDC, as well as ASC39, ASC36, and ASC35.
Ascletis publishes a corporate presentation dated August 2026 on its investor relations page.
Products and positioning
Ascletis' vision is to become the most innovative world-class biomedical company addressing global unmet medical needs in the area of metabolic diseases.
ASC30
A once-daily oral small molecule GLP-1R agonist for chronic weight management and diabetes.
ASC30_48FDC
A once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC48 (GIPR agonist).
ASC30_48_39FDC
A once-daily oral small molecule triple agonist, a fixed dose combination of ASC30 (GLP-1R agonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)).
ASC39
An eloralintide-like potent selective amylin receptor agonist (SARA) once-daily oral small molecule.
ASC30_39FDC
A once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC39 (amylin receptor agonist (SARA)).
ASC36
An amylin peptide, designed to be administered once monthly to once quarterly subcutaneously and once daily orally.
ASC35
A once-monthly subcutaneously administered GLP-1R/GIPR dual agonist.
Controversies
Recent events
- Unconfirmed
Ascletis expands ritonavir tablet production capacity[7]
Reported:
Ascletis expanded the annual production capacity of its ritonavir oral tablets to 100 million tablets, with the possibility of further increases based on market demand.
Sources7 sources
Cite this profile: Cite the canonical profile. /brand-wiki/ascletis-pharma-inc-china · Editorial policy · How profiles are compiled